HER2 Immunohistochemistry Testing May Not Be Needed in All Solid Tumours By Ogkologos - July 30, 2025 672 0 Facebook Twitter Google+ Pinterest WhatsApp Real-world experience from pan-tumour testing Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR For Women With Dense Breasts, An MRI May Be A Better... November 29, 2019 Woman Develops Breast Cancer After Double Mastectomy, Has to Have the... May 19, 2021 A PET-based, pCR-adapted Chemotherapy De-escalation Strategy Associated with an Excellent 3-year... April 5, 2024 FDA Approves Ivosidenib for Myelodysplastic Syndromes November 9, 2023 Load more HOT NEWS A bug in the system – the difficulties of linking the... EMA Recommends Granting a Conditional Marketing Authorisation for Selpercatinib Latest episode of our podcast for cancer researchers What the Budget 2021 means for research
